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RACIAL/ETHNIC DIFFERNCES IN THE PRESENTATION  
AND MANAGEMENT OF SEVERE BRONCHIOLITIS  
 
Jonathan Santiago and Carlos Camargo Jr. Department of Emergency Medicine, 
Massachusetts General Hospital, Boston, MA. (Sponsored by Karen Jubanyik, 
Department of Emergency Medicine, Yale University School of Medicine). 
 
 
We examined if racial/ethnic differences exist in the presentation and management of 
severe bronchiolitis using a 16-center, prospective cohort study from 2007-2010. 
Children <2 years hospitalized with a diagnosis of bronchiolitis were included. A 
structured interview, chart review, and 1-week phone follow-up were completed. 
Multivariable logistic regression was used to examine the independent association 
between race/ethnicity and diagnostic imaging, treatment, management, discharge on 
inhaled corticosteroids, and bronchiolitis relapse. Among 2,130 patients, 818 (38%) were 
non-Hispanic white (NHW), 511 (24%) were non-Hispanic black (NHB), and 801 (38%) 
were Hispanic. Compared with all groups, NHB children were most likely to receive 
albuterol before admission (OR 1.58; 95%CI, 1.20-2.07) and least likely to receive chest 
x-rays during hospitalization (OR 0.66; 95%CI, 0.49-0.90); Hispanic children were most 
likely to be discharged on inhaled corticosteroids (OR 1.92; 95%CI, 1.19-3.10). We 
observed differences between NHW and minority children regarding pre-admission 
albuterol use, inpatient diagnostic imaging, and prescription of inhaled corticosteroids at 
discharge; practices that deviate from the American Academy of Pediatrics guidelines. 
The causes of these differences require further study but they support implementation of 
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Bronchiolitis is the leading cause of hospitalization for infants in the U.S., costs 
more than $500 million annually, and has seen a 30% increase ($1.34 billion to $1.73 
billion) in related hospital charges from 2000-2009.
1-3
 Almost all children <2 years are 
infected with respiratory syncytial virus (RSV), the most common cause of bronchiolitis, 





Current American Academy of Pediatrics (AAP) guidelines state that routine use 
of bronchodilators, corticosteroids, and chest x-rays is not recommended and supportive 
care is strongly encouraged.
6
  However, a lack of consensus among clinicians persists 
regarding bronchiolitis management.
7-10
 Although minority children and those with a 
lower socioeconomic status (SES) in the U.S. are more likely to present with 
bronchiolitis to the emergency department (ED) and be subsequently admitted when 
compared to the general population,
11-13
 to our knowledge, no study has yet examined if 
race/ethnicity is independently associated with differences in the presentation and 
management of severe bronchiolitis (i.e., bronchiolitis causing hospitalization).  
 
Epidemiology & Microbiology 
Bronchiolitis secondary to RSV resulted in 34 million episodes of acute lower 
respiratory infections and 3.4 million hospitalizations in children <5 years globally in 
2005.
14
 In their landmark study to determine the global burden of RSV, Nair et al. listed 




infection (i.e., 66,000-199,000 deaths; 99% of mortality found in developing countries), 
after pneumococcal pneumonia and Haemophilus influenza type b. The toll of 
bronchiolitis is much less burdensome in the United States where 132,000-172,000 
pediatric hospitalizations are reported annually.
15,16
 Although primarily affecting the 
pediatric population, bronchiolitis can also be a source of significant morbidity and 
mortality in both the elderly and immunosuppressed patient populations.
17,18
 In fact, 
Thompson et al. suggest that up to a quarter of excess wintertime mortality secondary to 




Bronchiolitis incidence typically increases during seasonal outbreaks – November 
to April in the northern hemisphere and May to September in the southern hemisphere.
20
 
Although RSV is the most common cause of bronchiolitis, multiple viruses – 
parainfluenza, influenza A/B, adenovirus, human metapneumovirus, and rhinovirus – can 
causes bronchiolitis.  Bacterial causes of bronchiolitis include Mycoplasma pneumonia 
and Bordetella pertussis. Despite the variety in etiology, identifying the infectious agent 




Up to a quarter of patients hospitalized with bronchiolitis are found to be co-
infected with multiple agents.
23,24
 However, the implications of co-infection are unclear. 
Several studies have shown co-infection to result in higher hospitalization rates and 
longer hospital length of stay (LOS).
23,25
 Other data suggest no differences in severity, 
duration of illness, or hospital LOS.
26-28
  




Clinical Presentation & Management 
The AAP defines bronchiolitis as a clinical diagnosis consisting of “rhinitis, 
tachypnea, wheezing, cough, crackles, use of accessory muscles, and/or nasal flaring.”
6
 
In terms of clinical research, bronchiolitis is defined as the first episode of wheezing in a 
child younger than 12-24 months who has physical findings of a viral lower respiratory 
infection and no other explanation for wheezing.
29,30 
The natural history of the disease 
begins with upper respiratory tract symptoms followed by lower respiratory tract 
symptoms within 24-48 hours. Signs of moderate to severe respiratory distress include 
nasal flaring, respiratory rate >70/min, dyspnea, cyanosis, retractions, and often result in 
hospitalization. Disease progression typically peaks within 5-7 days. Average hospital 




Bronchiolitis is usually a self-limited disease. Risk factors for severe disease 
include prematurity (gestational age <37 weeks), age less than 12 weeks, chronic 
pulmonary disease (e.g., bronchopulmonary dysplasia), congenital and anatomic airway 
defects, congenital heart disease, immunodeficiency, and neurologic disease.
33-36
 The 
majority of infants infected with bronchiolitis are managed in the outpatient setting with 
supportive care. Supportive care includes suctioning, symptom control, and monitoring 
disease progression. Indications to seek medical care are commonly associated with 
episodes of apnea, cyanosis, fever, increased respiratory rate, increased work of 





There are currently no vaccines to prevent the most common causes of 
bronchiolitis (e.g., RSV, rhinovirus, etc.). Hand washing to limit the transmission of 
infections agents is the primary mode of prevention. Palivizumab, a humanized 
monoclonal antibody, provides defense against RSV and has been shown to decrease the 
risk of hospitalization among infants with comorbidities such as bronchopulmonary 
dysplasia, premature birth, and hemodynamically significant congenital disease. A 
multicenter randomized trial comparing palivizumab and placebo use in children with 
bronchopulmonary dysplasia or prematurity found a decrease in hospitalization rate of 




Supplemental oxygen is a first line treatment for severe bronchiolitis and should 
be provided to maintain oxygen saturation above 90%. Bass et al. showed that there 
carries a significant risk of adverse long-term cognitive and behavioral effects from 
chronic or intermittent hypoxemia (i.e., oxygen saturation between 90-94%) in cases such 
as severe bronchiolitis.
38
 Oxygen saturation read by pulse oximetry is the standard of care 
in determining whether an infected infant is hypoxemic. While arterial blood gases have 
been used to measure oxygen levels, pulse oximetry was found to overestimate arterial 
blood gases in a multicenter study if the oxygen saturation range was between 76-90%.
39
 
Conversely, oxygen saturation and arterial oxygen levels were similar if the oxygen 
saturation range was between 91-97%.  
 
Continuous positive airway pressure (CPAP) has become increasingly utilized to 
decrease work of breathing and hypercarbia.
40




alternative to endotracheal intubation and its associated risks. In a randomized control 
trial comparing nasal CPAP to standard treatment, Thia et al. demonstrated an 
improvement in ventilation for children with bronchiolitis undergoing CPAP treatment.
41
 
Similarly, Cambonie et al. demonstrated CPAP’s ability to decrease respiratory muscle 
overload and improve respiratory distress symptoms in children with severe acute viral 
bronchiolitis.
42
 However, despite its increasing use and positive findings, a systematic 
review found the evidence for CPAP use to be inconclusive due to the low 




The AAP guidelines recommend that inhaled bronchodilators (e.g., albuterol, 
epinephrine) not be used routinely. Multiple systematic reviews and meta-analyses of 
randomized trials have found use of bronchodilators to increase healthcare costs and 
adverse effects while not affecting overall outcome.
44,45
 For example, Gadomski et al. 
and Skjerven et al. demonstrated that the use of bronchodilators resulted in no clinical 
score improvement or decreased LOS for children with severe bronchiolitis.
46,47
 
However, bronchodilators can potentially provide short-term clinical improvement. 
Hartling et al. found that while use of bronchodilators did not affect LOS or admission 
within one week, they were associated with short-term clinical improvements.
44
 Despite 
the evidence, bronchodilators continue to be overprescribed in severe bronchiolitis cases.  
 
Systemic corticosteroids are also not recommended by the AAP. A double-
blinded randomized control trial by Panickar et al. demonstrated no difference in clinical 




when comparing oral prednisolone to placebo use.
48
 Furthermore, a meta-analysis 
conducted by Fernandes et al. in 2013 showed no difference in LOS, clinical score, 
admission and readmission rates for children taking corticosteroids.
49
 Their analysis 
consisted of 17 trials with 2,596 patients and is one of the largest and most recent reviews 
arguing against the use of systemic corticosteroids in bronchiolitis cases.  
 
Bronchiolitis infection during the first decade of life has been associated with 
increased risk for asthma, recurrent wheezing, and reduced pulmonary function.
50-52
 One 
subgroup analysis of a 20-year prospective follow-up study by Piippo-Savolainen et al. 
concluded that even infants with non-RSV bronchiolitis requiring hospital treatment were 
up to eight times more likely to be diagnosed with asthma in adulthood.
53
  Bronchiolitis’ 
association with asthma may have multiple implications on the part of clinicians 
attempting to stem the high prevalence of asthma, particularly in communities of color.   
 
Bronchiolitis Clinical and Prediction Rules 
 Severe bronchiolitis is associated with multiple clinical, environmental, and 
demographic factors. For example, previous studies have demonstrated gender 
differences in lung function as male infants are more likely to be hospitalized and die 
from bronchiolitis when compared to female infants.
54,55
 Urban environments and low 
socioeconomic status also predispose infants to severe bronchiolitis.
56,57
 In addition to the 
comorbidities previously discussed, household factors (e.g., crowding, passive smoke 
exposure), maternal smoking during pregnancy, and family atopy have been shown to 






One multicenter study and two single center studies have attempted to compare 
the relative effect of these variables as it relates to bronchiolitis severity.
33,62-63
 Opasvsky 
et al. examined the ability of prognostic models to predict a composite severity index or 
intensive care unit (ICU) admission regarding bronchiolitis infection.
64
 Despite their 
original attempts, many of these studies suffer from important limitations. Multiple 
models did not include important clinical factors (e.g., intubation outcomes) and ED 
assessments. Furthermore, the cohorts used to develop previous models were published 
prior to 1998 and the use of palivizumab.   
  
It is well-documented that admission rates for infants with bronchiolitis vary 
significantly when comparing general and pediatric EDs.
65
 Adding to the variability is 
also the noted difference in admission rates among pediatric ED attendings.
66
 
Establishing an evidence-based bronchiolitis severity index would be helpful in limiting 
the variability in clinical care and disposition received by patients. Furthermore, a 
bronchiolitis severity index can also guide a clinician’s decision to intervene in 





Health Disparities in Respiratory Disease 
Racial and ethnic differences in healthcare access and quality have been widely 
documented in the U.S.
69
 Prevalence of childhood asthma vary across race/ethnicity – 
8.8% for non-Hispanic white (NHW), 12.7% for non-Hispanic (NHB), 25.7% for Puerto 
Ricans, and 6.6% for Mexican-Americans.
70




racial/ethnic minorities have worse morbidity and mortality indices associated with 
respiratory diseases such as asthma when compared to NHW children.
71-74
 Meurer et al. 
demonstrated that NHB children were significantly more likely to visit pediatric 
emergency departments for asthma after controlling for multiple clinical and 
socioeconomic factors. Jane Miller’s research goes one step further by suggesting that 
lifetime income and sociodemographic characteristics do not explain the excess risks of 
asthma and ED visits associated with asthma among NHB children.
75
 She argues that 
asthma prevalence, hospitalization, and emergency room use declined with increasing 
income for all children except for NHB children.  
 
Although bronchiolitis is associated with an increased risk of asthma diagnosis, 
the role of race and ethnicity in the presentation and management of severe bronchiolitis 
remains unclear. The few studies that have provided some insight into the role 
race/ethnicity may play focused primarily on clinical objectives and not race/ethnicity. 
For example, Mansbach et al. suggested that multiple factors, Hispanic race/ethnicity 
among others, were associated with longer ED LOS for children with bronchiolitis.
76
 
Accordingly, he concluded that optimizing translation services may help shorten ED LOS 
in bronchiolitis cases. Damore et al. demonstrated that bronchiolitic children with public 
insurance, more often a variable associated with Hispanic and NHB children, were less 
likely to receive inhaled beta-agonists or antibiotics in the week before the ED visit while 
children without insurance were less likely to have a PCP or receive laboratory testing in 
the ED.
77
 However, her study found no difference between insurance groups when it 




saturation, and retractions), and ED treatments (e.g., inhaled beta-agonists, inhaled 
racemic epinephrine, systemic corticosteroids, and antibiotics). She concludes her 
analysis suggesting that all children, regardless of insurance status, should receive similar 
care. 
 
Contrary to the studies previously described, two analyses looking at bronchiolitis 
associated ICU admissions and unscheduled visits post ED discharge found no 
differences across race/ethnicity.
78,79
 ICU admission secondary to bronchiolitis was found 
to be associated with four independent factors: age <2 months, an ED visit in the past 
week, moderate/severe retractions, and inadequate oral intake. Norwood et al. 
demonstrated that three predictors (e.g., age <2 months, male sex, and previous 
hospitalization) were associated with unscheduled visits within 2 weeks of ED discharge. 
In a comparable asthma study of young children, Chandra et al. did not identify any 
racial/ethnic differences regarding inpatient treatment and outcomes; however, he did 
note that Hispanic children were less likely to receive an asthma action plan compared to 




STATEMENT OF PURPOSE 
This study seeks to address the knowledge gap by examining prospective data 
from a multicenter study designed to evaluate factors related to bronchiolitis 
hospitalization. The primary objective is to determine if racial/ethnic differences exist in 
the presentation and management of severe bronchiolitis. By utilizing race/ethnicity as a 




standpoint (i.e., unequal care based on race/ethnicity) and from a clinical perspective (i.e., 
the potential of certain practices, such as clinical care pathways, to increase the likelihood 
of equitable treatment). 
 
HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis 
Racial/ethnic differences exist in the presentation and management of severe 
bronchiolitis; Hispanic and NHB children present with a more severe case of 
bronchiolitis and are less likely to receive standard treatments and care when compared to 
NHW children.   
 
Specific Aims 
1. Calculate a respiratory distress severity score for NHW, Hispanic, and NHB 
children with severe bronchiolitis.    
2. Determine if racial/ethnic differences exist in the use of albuterol, 
corticosteroids, and chest x-rays during pre-admission visit and 
hospitalization. 
3. Determine if racial/ethnic differences exist in the use of intensive respiratory 
support (i.e., CPAP, intubation, and/or ICU admission). 
4. Determine if racial/ethnic differences exist regarding LOS, discharge on 








We conducted a multicenter prospective cohort for 3 consecutive years (2007-
2010) as part of the Multicenter Airway Research Collaboration (MARC), a division of 
the Emergency Medicine Network (EMNet) (www.emnet-usa.org). Sixteen hospitals in 
12 states (see Appendix) participated from November 1
st
 until March 31
st
 in each study 
year. The number of sites varied by year: 13 sites in year 1, 16 sites in year 2, and 14 sites 
in year 3. At the beginning of each month, site investigators used a standardized protocol 
to enroll a target number of patients from the inpatient wards and ICU. Once the site 
reached their target enrollment for that month, the investigators would stop enrollment 
until the beginning of the next month. 
 
All patients were treated at the discretion of their physician. Inclusion criteria 
were hospital admission with physician diagnosis of bronchiolitis, age <2 years, and 
ability of the child’s guardian (e.g., parent) to give informed consent. Patients were 
enrolled within 18 hours of admission. Physician diagnosis of bronchiolitis followed the 
AAP definition of a child with an acute respiratory illness with some combination of 
rhinitis, cough, tachypnea, wheezing, crackles, and/or retractions. The exclusion criteria 
were previous enrollment and if a patient was transferred to a participating site hospital 
>48 hours after the initial admission. All consent and data forms were translated into 







Site investigators used a standardized protocol to enroll 2,207 patients admitted 
with bronchiolitis. Investigators conducted a structured interview that assessed patients’ 
demographic characteristics, medical and environmental history, duration of symptoms, 
and details of the acute illness. Race/ethnicity was assigned by report of the child’s 
guardian to standard U.S. Census groups. For the purpose of this analysis, mutually 
exclusive race/ethnicity categories were determined: NHW, NHB, or Hispanic. Non-
Hispanic patients who identified as being both white and black were categorized as NHB. 
Patients were excluded from analysis if neither white or black race nor Hispanic ethnicity 
were reported (e.g., if only Asian race was reported) because of small numbers (n=67), as 
were patients missing all race/ethnicity data (n=10). This resulted in a total of 2,130 
(97%) patients in our analytical dataset. SES was assessed with two variables: insurance 
status (public, private, none) and family income, estimated by matching patients’ home 
ZIP codes and year of enrollment to ZIP code-based median household annual incomes 




ED and daily clinical data, including laboratory tests (e.g., complete blood count, 
basic metabolic panel, urine analysis, blood culture, etc.), respiratory rates, oxygen 
saturation, medical management, and disposition were obtained by medical chart review. 
Additionally, in an attempt to evaluate bronchiolitis severity at presentation, a modified 
Respiratory Distress Severity Score (RDSS) was calculated based on four assessments 
made during the pre-admission visit (i.e., ED or office visit before hospital admission): 




difficulty, or moderate/severe), and retractions (none, mild, or moderate/severe).
82
 Each 
component was assigned a score of 0, 1 or, 2, with the exception of wheeze which was 
assigned either a 0 (no wheeze) or a 2 (wheeze), and then summed for a possible total 
score of 0 to 8.  
 
Lastly, a follow-up telephone interview was conducted one week after hospital 
discharge for each enrolled patient. Interviews assessed acute relapse, recent symptoms, 
and provided additional endpoints for longitudinal analysis of specific symptoms. All 
data were manually reviewed at the EMNet Coordinating Center and site investigators 
were queried about missing data and discrepancies identified. 
 
Outcome Measures 
The major outcomes of this analysis were: albuterol and corticosteroid (inhaled or 
systemic) use during pre-admission visit and hospitalization, chest x-rays performed at 
pre-admission visit and hospitalization, need for intensive respiratory support (i.e., 
receiving continuous positive airway pressure (CPAP), intubation, or ICU admission), 
hospital LOS ≥3 days, discharge on inhaled corticosteroids, and relapse of bronchiolitis 
requiring medical attention and a change of medication within one week of discharge. 
 
Statistical Analysis 
Stata 11.2 (Stata Corp, College Station, TX) was used for all analyses. We 
examined unadjusted differences between racial/ethnic groups and clinical presentation, 
patient management, and outcomes using χ
2




appropriate, with results reported as proportions with 95% confidence intervals (CI) or 
medians with interquartile ranges (IQR). Imputed values, calculated with the Stata impute 
command, were used to calculate the RDSS when one of the four components was 
missing; patients missing more than one component were not assigned an RDSS value. 
Multivariable logistic regression was conducted to evaluate the adjusted association 
between race/ethnicity and the outcomes listed above. Besides race/ethnicity, all 
multivariable models included the demographic variables of age, sex, insurance, and 
median household income. Other factors were considered for inclusion if they were 
associated with the outcome in unadjusted analyses (P<0.20) or deemed clinically 
relevant. All models were adjusted for the possibility of clustering by site. Results are 
reported for the race/ethnicity factor as odds ratios (OR) with 95% CI. 
 
RESULTS 
Of the 2,130 subjects included in this analysis, 818 (38%) were NHW, 511 (24%) 
were NHB, and 801 (38%) were Hispanic. The median age for children was 4.0 months 
(IQR 1.8-8.5 months) and 60% were male. Most children were publicly insured (65%), 
31% had private insurance, and approximately 4% had no insurance. The median 
household income defined by patient ZIP code was $51,810 (IQR $39,916-$66,272) and 
nearly all children (97%) had a primary care provider (PCP). Approximately 21% of all 
children had relevant comorbidities and 17% of children were enrolled from the ICU. 





The unadjusted associations between race/ethnicity and other demographic and 
historical characteristics are shown in Table 1. NHB and Hispanic children were more 
likely to have public insurance, live in a ZIP code with a lower median household 
income, and less likely to have relevant major comorbidities when compared to NHW 
children. NHB children were more likely to experience second-hand smoke exposure, 
have been previously intubated, and received palivizumab. With regard to care received 
the week before hospitalization, NHW children were more likely to have visited their 
PCP, taken corticosteroids and/or antibiotics, and least likely to have visited an ED when 


















TABLE 1: Demographic and Clinical Characteristics of Subjects Before the Pre-admission 
Visit*, by Race/Ethnicity 
 
 
White                
(non-Hispanic) 
n=818 







 column % P 
Demographic characteristics     
Age (months), median (IQR) 3.2 (1.5-7.4) 5.0 (1.9-9.2) 4.4 (2.0-9.1) <0.001 
Female 39.7 40.9 40.4 0.91 
Insurance    <0.001 
Private 56.7 17.0 13.1  
Medicaid 32.8 70.9 77.5  
Other public 6.8 7.6 4.2  
None 3.7 4.6 5.3  
Median household income by 











Has primary care provider 98.5 97.3 95.4 0.001 
     
History     
Gestational age at birth    0.002 
<32 weeks 4.5 9.2 6.6  
32 - 35 weeks 5.7 8.8 6.0  





White                
(non-Hispanic) 
n=818 






 column % P 
≥37 weeks 76.0 71.4 76.9  
Missing 0.4 0.6 0.7  
Weight when born    <0.001 
<3 pounds 3.3 6.9 5.8  
3-4.9 pounds 6.8 11.9 6.2  
5-6.9 pounds 33.4 39.7 33.2  
> 7 pounds 55.8 40.3 53.6  
     Missing 0.7 1.4 1.4  
Kept in an ICU, premature 
nursery, or any type of special 
care facility when born 
24.5 29.7 24.9 0.07 
Breast fed 62.3 49.1 65.5 <0.001 
Attends daycare 20.7 25.2 13.3 <0.001 
Number of other children  
(<18 old) living in home 
   <0.001 
1 24.2 25.6 17.0  
2 42.7 29.2 28.3  
≥3 33.1 45.2 54.7  
Neither parent has asthma 66.1 56.6 77.7 <0.001 
Maternal smoking during 
pregnancy 





White                
(non-Hispanic) 
n=818 






 column % P 
 









History of wheezing 21.1 25.9 21.8 0.12 
Ever intubated 9.5 13.2 9.2 0.05 
Major relevant comorbidities** 23.6 21.1 18.2 0.03 
Received palivizumab 
(respiratory syncvtial virus 
vaccine) 
8.7 12.7 8.9 0.04 
Received influenza vaccine this 
year 
20.2 24.7 21.2 0.15 
In past 12 months, admitted 
overnight to hospital for 
bronchiolitis/wheezing/reactive 
airway disease 
45.0 57.9 55.9 0.06 
In past 12 months, admitted 
overnight to hospital for 
pneumonia 
16.1 14.9 25.0 0.049 
     
Current illness 
(before index visit) 
    
Any primary care provider or 
clinic visits during past week 





White                
(non-Hispanic) 
n=818 






 column % P 
Any ED visits during past week 29.1 30.3 34.6 0.049 
Over the past week, used 
inhaled bronchodilator 
40.6 36.2 37.0 0.18 
Over the past week, used 
inhaled/nebulized 
corticosteroids 
8.7 8.1 7.7 0.76 
Over the past week, taken any 
steroid liquids or pills or shots 
for bronchiolitis 
12.8 11.7 8.3 0.012 
Over the past week, taken 
antibiotics 
21.9 17.0 17.9 0.045 
Onset of difficulty breathing 
before admission 
   0.03 
None 2.0 2.2 2.4  
<24 hours 28.8 27.2 25.1  
1-3 days 41.1 41.6 45.9  
4-7 days 22.1 19.1 21.2  
> 7days 6.0 9.9 5.3  
Over the past 24 hours, the level 
of discomfort or distress felt by 
child because of symptoms 
   <0.001 





White                
(non-Hispanic) 
n=818 






 column % P 











Abbreviations: IQR, interquartile range; ED, emergency department 
* Pre-admission visit is the emergency department or office visit preceding hospital 
admission. 
** Major relevant comorbid disorders included reactive airway disease or asthma, spastic 
di/quadriplegia, chronic lung disease, seizure disorder, immunodeficiency, congenital heart 

















The unadjusted associations between race/ethnicity and clinical characteristics at 
pre-admission visit and hospital admission are shown in Table 2. Significant differences 
across race/ethnicity were found regarding why guardians brought their child to the 
hospital. Febrile Hispanic children and NHW children not drinking well were two 
reasons for seeking care that showed the strongest association. RDSS values were 
calculated for 2,130 children; 1,752 (82%) RDSS values contained all four components. 
Of those requiring imputed values, 234 (11%) were missing one component and 139 
(7%) were missing more than one component. Per RDSS scores, NHB children presented 
with a more severe case of bronchiolitis when compared to NHW and Hispanic children. 
During admission, minority children were more likely to receive nebulized albuterol and 
less likely to visit the ICU. NHB children received the least inpatient laboratory testing 



















White                
(non-Hispanic) 
n=818 






 column % P 
  Pre-admission clinical findings 
and treatments 
    
Reason Brought To Hospital:     
Fever 29.7 30.2 40.7 <0.001 
Fussy 32.6 31.6 28.4 0.18 
Ear Infection 6.0 4.3 4.4 0.23 
Not drinking well 35.0 27.5 27.2 0.001 
Cough 54.1 55.5 61.3 0.009 
Other reasons 29.0 27.6 23.5 0.04 
Apnea 8.5 6.2 6.1 0.11 
Respiratory rate 
(breaths/minute) 
   0.001 
<40 23.8 18.2 28.1  
40-49 30.8 30.7 29.3  
50-59 17.6 15.5 16.0  
≥60 27.8 35.6 26.6  
Presence of cough 83.0 88.0 87.0 0.045 
Presence of wheezing 63.0 69.0 63.0 0.42 





White                
(non-Hispanic) 
n=818 






 column % P 
Fever  
(Temperature ≥100.4°F) 
22.7 28.5 35.4 <0.001 
Retractions    0.002 
None 22.9 19.0 23.0  
Mild 39.4 41.7 44.4  
Moderate/severe 28.4 31.1 28.1  
Missing 9.4 8.2 4.5  
Air entry on auscultation    0.01 
Normal 39.6 31.7 33.6  
Mild difficulty 31.4 33.5 36.3  
Moderate difficulty 11.0 14.3 14.1  
Severe difficulty 2.0 2.3 2.6  
Missing 16.0 18.2 13.4  
Oxygen saturation on 
 room air <90 
12.2 9.8 11.8 0.37 
Given nebulized albuterol 53.0 65.0 63.0 <0.001 
Given nebulized epinephrine 15.4 20.4 18.4 0.06 
Given steroids, inhaled or 
systemic 
16.0 20.5 19.4 0.08 





White                
(non-Hispanic) 
n=818 






 column % P 
Oral Intake    <0.001 
Adequate 41.3 50.7 40.8  
Inadequate 43.5 32.5 47.7  
Missing 15.2 16.8 11.5  
IV placed 56.9 51.5 61.9 0.001 
Any laboratory tests 86.3 91.3 88.0 0.02 
Chest x-ray 59.0 64.0 65.0 0.03 
RDSS, tertiles    <0.001 
1 (≤3.00) 36.0 24.0 34.0  
2 (3.011-5.00) 30.0 33.0 34.0  
3 (>5) 25.0 36.0 27.0  
Not Calculated 9.0 6.0 4.0  
     
Virology Results     
Respiratory syncytial virus 75.9 67.5 71.0 0.003 
Human rhinovirus 23.8 30.1 25.0 0.03 









White                
(non-Hispanic) 
n=818 






 column % P 
Inpatient clinical findings  
and treatments 
    
Length of stay ≥3 days 46.5 39.3 45.4 0.03 
Ever in observation unit 8.6 7.8 4.0 0.001 
Ever in regular ward 89.4 93.0 94.5 0.001 
Ever in step-down unit 5.0 3.2 7.8 0.002 
Ever in ICU 20.3 15.0 15.9 0.02 
Required CPAP or intubation 7.7 4.6 8.8 0.02 
Given nebulized albuterol 37.6 48.0 46.7 <0.001 
Given nebulized epinephrine 10.7 14.9 13.0 0.07 
Given steroids, inhaled or 
systemic 
21.3 27.3 23.5 0.047 
Given antibiotics 38.9 34.3 38.6 0.19 
Received IV fluids 53.1 45.6 57.1 <0.001 
Any laboratory tests 52.2 41.6 51.7 <0.001 
Chest x-ray 27.1 18.6 22.9 0.002 
 
Abbreviations: RDSS, Respiratory Distress Severity Score; ICU, intensive care unit; CPAP, 








Discharge treatment and outcomes at one week follow-up are shown in Table 3. 
A total of 1,771 patients (83%) were reached by telephone. No statistically significant 
differences between racial/ethnic groups were found regarding two primary outcomes, 



























White                
(non-Hispanic) 
n=818 







column % P 
Discharged on inhaled 
corticosteroids 
9.5 11.1 13.3 0.08 
Discharged on oral 
corticosteroids 
9.8 12.4 8.5 0.11 
Child’s condition at 1 week 
follow-up compared to on 
discharge 
   0.001 
 Much worse/worse 1.8 0.7 0.4  
About the same 3.4 6.4 2.5  
Better 38.2 39.1 34.2  
All better 56.6 53.7 62.9  
Child’s cough at 1 week 
follow-up compared to on 
discharge 
   0.10 
Much worse/worse 2.1 1.2 1.0  
About the same 5.0 8.4 5.2  
Better 29.4 31.2 28.6  
All better 63.5 59.2 65.2  






Given the large potential for confounding regarding our initial findings, we 
examined multivariable-adjusted associations of race/ethnicity and bronchiolitis 
management (Table 4). Receiving albuterol during the pre-admission visit and chest x-
rays during hospitalization remained significantly associated with race/ethnicity in 
adjusted analyses, as NHB children were most likely to receive albuterol during the pre-
admission visit but least likely to receive chest x-rays during hospitalization. Several 
outcomes with statistically significant differences found during unadjusted analyses (e.g., 
chest x-rays at pre-admission visit, albuterol during hospitalization, CPAP/intubation use, 
ICU admission, and LOS) were not independently associated with race/ethnicity in 
multivariable models. By contrast, adjusted analyses revealed Hispanic children as 
significantly more likely to be discharged on inhaled corticosteroids when compared to 
NHW and NHB children; this association had borderline statistical significance (P=0.08) 
in the unadjusted analysis. Lastly, we observed no significant racial/ethnic differences 
with respect to corticosteroids given at pre-admission visit or hospitalization as well as no 












TABLE 4: Multivariable Results of Clinical Decisions and Outcomes among Children  




















Preadmission visit       
 Chest x-ray* 1.00 (Reference) 1.06 (0.83-1.36) 1.09 (0.74-1.60) 
 Albuterol use
₳
 1.00 (Reference) 1.58 (1.20-2.07) 1.42 (0.89-2.26) 
 Steroid use,  
 inhaled or systemic
§
 
1.00 (Reference) 1.05 (0.72-1.54) 1.11 (0.75-1.65) 
During hospitalization       
 Chest x-ray
†
 1.00 (Reference) 0.66 (0.49-0.90) 0.95 (0.60-1.50) 
 Albuterol use
₪
 1.00 (Reference) 1.21 (0.82-1.79) 1.23 (0.63-2.38) 
 Steroid use, 
 inhaled or systemic
#
 
1.00 (Reference) 1.13 (0.72-1.80) 1.19 (0.79-1.79) 
 ICU care
∩
 1.00 (Reference) 0.74 (0.42-1.29) 0.87 (0.63-1.21) 
 Required CPAP/intubation
¶
 1.00 (Reference) 0.72 (0.36-1.41) 1.84 (0.93-3.64) 
 Length of stay ≥3 days
€
 1.00 (Reference) 0.77 (0.58-1.03) 1.05 (0.76-1.47) 
Discharge       




1.00 (Reference) 1.31 (0.86-2.00) 1.92 (1.19-3.10) 
 Bronchiolitis relapse
¥
 1.00 (Reference) 1.08 (0.62-1.87) 0.96 (0.55-1.65) 
 
Abbreviations: OR, odds ratio; CI, confidence interval; ICU, intensive care unit; CPAP, 
continuous positive airway pressure. 
 




*Also control for gestational age, parental asthma, past pneumonia or bronchiolitis admission, 
discomfort and dyspnea at home, chief complaint, virology.  
₳
Also control for birth weight, medications and dyspnea before preadmission, virology. 
§
Also control for birth weight, NICU, children at home, parental asthma, comorbidity, flu 
shot, medications at home, virology. 
†Also control for gestational age, birth weight, prenatal smoking, palivizumab, past 
pneumonia admission, steroids before preadmission, preadmission oral intake, O2 
saturation, RDSS, apnea, virology, antibiotics, and labs.  
₪
Also control for gestational age, wheezing history, flu shot, discomfort at home, chief 
complaint, preadmission medications, labs and virology, RDSS.  
#
Also control for breast feeding, parental asthma, wheezing history, comorbidities, flu 
shot, past pneumonia admission, medications before preadmission, preadmission fever, 
O2 saturation, RDSS, apnea, virology, medications, and labs. 
∩
Also control for family history, birth weight, breast feeding, prenatal smoking, 
antibiotics and discomfort before preadmission, chief complaint, preadmission apnea, 
O2 saturation, RDSS, antibiotics, intravenous line, and labs.  
¶
Also control for birth weight, prenatal smoking, past bronchiolitis admission, steroids 
before preadmission, preadmission O2 saturation, RDSS, apnea, intravenous line, and 
antibiotics. 
€
Also control for birth weight, NICU, other children at home, prenatal smoking, 
palivizumab, discomfort and dyspnea before preadmission, chief complaint, 
preadmission oral intake, O2 saturation, RDSS, virology, and epinephrine. 
$
Also control for prenatal smoking, wheezing history, palivizumab, medications before 
preadmission, chief complaint, oral intake, step down, ICU, inpatient steroids, and labs.  
¥
Also control for parental asthma, intubation history, past bronchiolitis admission, 
virology, and LOS. 
 














It is unclear if management and treatment differences found in children with 
severe bronchiolitis are associated with race/ethnicity. We sought to determine if such 
differences exist by analyzing data from a prospective multicenter cohort study. 
Differences in management and treatment are discussed in the context of AAP guidelines 
as they are widely used in clinical practice. 
 
The RDSS was used to help assess severity of illness across race/ethnicity. NHB 
children had the highest RDSS score (i.e., most severe bronchiolitis presentation) 
compared to NHW and Hispanic children. The reason for this difference in severity is 
unclear but one potential explanation may be that minority communities lack access to 
care and as a result delay care and treatment for respiratory disease until care seems 
absolutely necessary. Drawing on the Institute of Medicine’s Report on Access to Care, 
Rand et al. argues that excess respiratory disease morbidity may be attributed to personal 
barriers (e.g., lack of parental knowledge about respiratory disease management, folk 
illness beliefs, and behaviors), structural barriers (e.g., lack of primary caretaker, 
organizational impediments), and financial barriers (e.g., trouble paying for primary care 
visits or prescriptions).
83
 Indeed, in our sample, minority children were less likely to visit 
their PCP and take corticosteroids the week before hospitalization when compared with 
NHW children. Our finding runs counter to a similar study by Boudreaux et al. that found 
no association between race/ethnicity and the clinical presentation of children with acute 
asthma during the pre-admission setting.
84 
The more severe bronchiolitis presentation 




hospital LOS (≥3 days). However, our multivariable analysis found no difference in LOS 
across racial/ethnic groups. This LOS finding is intriguing given previous studies 
suggesting that minorities, of diverse ages and with diverse diagnoses, were more likely 
to have a shorter LOS (as well as less likely to be admitted to the ICU with a similar 
diagnosis) when compared to non-minorities.
85,86
 Additionally, because our study 





Our findings also shed light on how differences in bronchiolitis management 
relate to AAP guidelines. According to the AAP, corticosteroid medications should not 
be used routinely in the management of bronchiolitis. Despite this recommendation, 
previous reports indicate that up to 60% of infants with severe bronchiolitis receive 
corticosteroid therapy.
88,89
 Our finding that Hispanic children with severe bronchiolitis 
were most likely to be discharged on inhaled corticosteroids is potentially concerning as 
it exposes a subset of children to treatment that is not recommended. On the other hand, 
given the increased risk of future asthma in Hispanic communities, a higher use of 
inhaled corticosteroids might be seen as appropriate. Either way, our findings are 
inconsistent with related studies concluding that racial minority pediatric patients with 
asthma were less likely to receive inhaled corticosteroids.
90-93
 Similarly, NHB children 
were most likely to receive albuterol during the pre-admission visit on multivariable 
analysis. Although a trial dose of albuterol may be common practice in treating severe 
bronchiolitis, AAP recommendations do not support its routine application. Increased 




severity at presentation among NHB children (as indicated by the RDSS). Potential 
reasons for these two differences in treatment remain unclear. They may represent 
medical management efforts by discharging physicians to prescribe: (1) corticosteroids to 
racial/ethnic communities with a higher risk of childhood asthma; (2) albuterol to 
children presenting with a more severe case of bronchiolitis. These possibilities merit 
further study. 
 
The AAP also recommends diagnosis of bronchiolitis on the basis of history and 
physical examination; laboratory and radiologic studies should not be routinely used for 
diagnostic purposes. Although it is possible for chest radiograph abnormalities to be 
consistent with bronchiolitis, there is little evidence that an abnormal finding is 
associated with disease severity.
94
 The clinical value of diagnostic testing in children with 
bronchiolitis is not well supported by evidence and limiting exposure to radiation should 
be a priority.
95
 Our analysis found that NHW and Hispanic children were more likely to 
receive chest x-rays while hospitalized when compared with NHB children. Unnecessary 
and increased radiation exposure in children is potentially harmful and warrants 
intervention to minimize risk. 
 
Establishing systematic clinical care pathways in bronchiolitis management may 
address the practice variation found nationwide and across race/ethnicity in this study. 
While clinical guidelines provide general recommendations, clinical care pathways are 
defined treatment protocols aiming to standardize and optimize patient outcomes and 




systems has increased recently as a result of their favorable associations. In a large 
systematic review consisting of 27 studies involving 11,398 patients, Rotter et al. found 
that clinical care pathways helped reduce in-hospital medical complications and improve 
documentation without negatively impacting LOS and hospital costs.
96
 With respect to 
bronchiolitis, such treatment protocols have proven to be successful. Wilson et al. found 
that the implementation of clinical care pathways in bronchiolitis cases reduced 
inappropriate antibiotic use from 27% to 9% in addition to reducing healthcare costs and 
LOS.
97
 Similarly, Cheney et al. proved that their adoption could reduce readmission 
rates.
98
 The inclusion of clinical pathways in her study not only reduced readmission rates 
within 2 weeks from 7.2% to <1%, but also decreased the number of children receiving 
supplemental fluids and steroids. Ralston et al. went one step further by analyzing the 
results of a voluntary quality improvement collaborative of pediatric hospitals from 17 
centers. The goal of the collaborative, Value in Inpatient Pediatrics, was to link academic 
and community-based hospitalist groups to disseminate evidence-based management 
strategies for bronchiolitis. In his landmark study observing 11,568 bronchiolitis 
hospitalizations post intervention, he demonstrated a 46% reduction in overall volume of 




Notwithstanding the differences found in this study, management of children with 
bronchiolitis was, in many respects, comparable across racial/ethnic groups. For example, 
our multivariable analysis found no significant differences across racial/ethnic groups 
with respect to chest x-rays and corticosteroid use during the pre-admission visit, 




CPAP/intubation, ICU admission, hospital LOS, or likelihood of a bronchiolitis-related 
relapse. The general lack of race/ethnic differences is consistent with similar research on 




This study has potential limitations. The hospitals participating in the study are 
predominantly urban, academically-affiliated hospitals. This may result in findings that 
are less generalizable to rural and community hospitals. Second, the race/ethnicity 
classification used does not take into consideration the diversity and complexity of 
defining race/ethnicity in the U.S. Third, bronchiolitis is defined as a clinical diagnosis 
that can encapsulate multiple lower respiratory infection diagnoses. As a result, there may 
have been variability in clinical and institutional practice. An additional limitation was 
utilizing RDSS to assess bronchiolitis severity. While there is currently no validated, 
universally-accepted score to assess bronchiolitis severity, several scores are available in 
the literature with varying performance. Lastly, the ZIP code-based median household 
incomes used to assess SES are higher than federal data in similar geographic locations, 
potentially resulting in findings that are less generalizable.  
 
CONCLUSION 
This multicenter prospective cohort study found several differences in 
bronchiolitis presentation and management among children stratified by race/ethnicity in 
16 geographically-dispersed sites after controlling for multiple factors including SES. 
Our analysis showed that, when compared to NHW children, NHB children were more 




x-rays as inpatients; Hispanic children were more likely to be discharged on inhaled 
corticosteroids. These differences are concerning for two reasons: (1) based on current 
evidence, race/ethnicity should not affect care in children with severe bronchiolitis; and 
(2) the observed differences in diagnostic testing and treatment are not recommended by 
the evidence-based AAP guidelines. It is also important to note that these differences do 
not demonstrate that a specific race/ethnicity received better or worse clinical care. The 
goal of this analysis was not to determine the effectiveness of certain management 
tendencies in children with severe bronchiolitis, but rather to examine differences in the 
presentation and management of children from different racial/ethnic groups. The causes 
for the observed findings require further study. In the meantime, we suggest increasing 
the number of hospitals that incorporate clinical care pathways for severe bronchiolitis to 
control variation in practice and limit the impact that race/ethnicity may have in the 
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